Problem

Alga Biosciences targets enteric methane from cattle, produced when microbes digest cellulose in the animals’ rumen. The climate pain is substantial: methane is about 25 times more potent than CO₂ as a greenhouse gas, and cattle are a major agricultural source. The economic pain is also direct for producers: roughly 12% of the calories fed to cattle can be lost as methane, meaning farmers pay for feed energy that does not become meat or milk.

The killer use case is routine supplementation of beef and dairy cattle, where reducing methane can simultaneously lower emissions and improve feed economics. Alga says its supplement can reduce methane emissions by up to 97%, while using less energy for methane production means a cow can require substantially less feed to grow at the same rate. In the company’s framing, this turns a climate intervention into a potential source of additional cash for cattle owners.

Product / Service

Alga sells a biochemically modified, algae-based cattle-feed additive designed to suppress methane formation in the rumen. It is intended to be mixed into existing cattle rations rather than require new farm infrastructure: the company says the additive can make up roughly 0.5% of the diet, while another company profile describes use at under 1% of daily ration. The underlying approach uses algae-derived biochemistry, including red-seaweed-related compounds, to inhibit methane production during digestion.

The claimed benefits are unusually high methane reduction at low inclusion and low cost. Alga reports reductions of up to 97% in beef cattle and 90% in dairy cows, and says the product is inexpensive and safe for cattle. The broader operating proposition is therefore a feed product that can be adopted through normal cattle-industry channels while helping producers reduce feed waste, emissions and potentially their exposure to carbon-related costs.

Market

Alga competes in the emerging livestock-feed and enteric-methane-inhibitor market within climate agriculture. The main alternatives include Bovaer, the 3-NOP product developed by DSM-Firmenich and marketed in the U.S. by Elanco, and FutureFeed’s Asparagopsis-based seaweed ingredient. Bovaer is the most commercially advanced and widely approved option, but reported reductions are approximately 30% in dairy cattle and up to 45% in beef cattle; FutureFeed’s seaweed approach has shown reductions of 80% or more. Alga’s positioning is a potentially more scalable and lower-cost algae-based alternative with higher claimed reductions, though efficacy and economics are not directly comparable across all trials and products.

The company is not best characterized as purely pre-revenue or still at laboratory proof-of-concept. It was founded in 2021, entered Y Combinator in Winter 2022, raised at least $4 million by April 2023, completed live-animal trials, and was preparing larger commercial pilots at production capacity reported in the tens of thousands of cattle per day. By 2025, an Unreasonable profile reported that Alga had produced the first 1 million pounds of low-methane beef in the U.S. and received grants from the USDA, CDFA and universities. Public sources establish meaningful pilot and early commercial traction, but do not provide a dependable current revenue figure, so the scale and durability of commercialization remain less clear than the company’s technical claims.